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Objectives: We investigated the efficacy of the novel antimicrobial agent SMT19969 in treating simulated
Clostridium difficile infection using an in vitro human gut model.
Methods: Concentrations of the predominant cultivable members of the indigenous gut microfloras and C. diffi-
cile (total and spore counts) were determined by viable counting. Cytotoxin titres were determined using cell
cytotoxicity and expressed as log10 relative units (RU). Clindamycin was used to induce simulated C. difficile
PCR ribotype 027 infection. Once high-level cytotoxin titres (≥4 RU) were observed, SMT19969 was instilled for
7 days. Two SMT19969 dosing regimens (31.25 and 62.5 mg/L four times daily) were evaluated simultaneously in
separate experiments. MICs of SMT19969 were determined against 30 genotypically distinct C. difficile ribotypes.
Results: SMT19969 was 7- and 17-fold more active against C. difficile than metronidazole and vancomycin,
respectively, against a panel of genotypically distinct isolates (P,0.05). Both SMT19969 dosing regimens demon-
strated little antimicrobial activity against indigenous gutmicroflora groups except clostridia. SMT19969 inhibited
C. difficile growth and repressed C. difficile cytotoxin titres in the gut model.
Conclusions: These data suggest that SMT19969 is a narrow-spectrum and potent antimicrobial agent against
C. difficile. Additional studies evaluating SMT19969 in other models of C. difficile infection are warranted, with
human studies to place these gut model observations in context.
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Introduction
Clostridium difficile infection (CDI) is the leading cause of infec-
tious nosocomial diarrhoea. It is the aetiological agent of pseudo-
membranous colitis and is implicated in 30% of cases of
antibiotic-associated diarrhoea.1,2 Most antimicrobials have
been implicated, but clindamycin, third-generation cephalospor-
ins and aminopenicillins are particularly noted for their propensity
to induce CDI.3 Despite improved clinical management strategies
for CDI, healthcare costs for treating CDI remain high and have
been estimated in the USA at US$1.1–3.2 billion.4,5 Following
the emergence of C. difficile PCR ribotype 027, the incidence of
CDI in the UK increased markedly, but has subsequently declined.
Metronidazole and vancomycin were considered for many years
to be similarly effective, but later studies indicated that the former
antimicrobial agent is inferior, particularly in severe CDI.6 – 10
Fidaxomicin is active in vitro and in vivo against C. difficile,11,12
and although a fidaxomicin-resistant C. difficile was isolated
from a recurrent CDI patient (MIC of 16 mg/L) during Phase III
clinical trials,11 the significance of this result remains to be deter-
mined. Recurrent CDI remains a therapeutic challenge, despite
the recent availability of fidaxomicin, which is less efficacious
against CDI due to PCR ribotype 027.6
We have previously described an in vitro human gut model of
CDI that yields results consistent with in vivo data. The aim of this
study was to evaluate the effects of the investigational drug
SMT19969 on clindamycin-induced growth and toxin production
in this gut model, using an epidemic C. difficile NAP1/027 strain.
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Materials and methods
C. difficile strains
The C. difficile PCR ribotype 027 strain (CD 210) evaluated in the in vitro
human gut model was isolated during an outbreak of CDI at the Maine
Medical Centre (Portland, ME, USA) in 2005 and was supplied courtesy of
Dr Rob Owens. A panel of clinical C. difficile strains were evaluated for
their antimicrobial susceptibilities to metronidazole, vancomycin and
SMT19969, comprising 30 genotypically distinct PCR ribotypes (PCR ribo-
types: 002, 003, 005, 009, 010, 011, 014, 015, 017, 018, 019, 014/20,
023, 026, 027, 035, 044, 045, 046, 050, 056, 060, 063, 064, 067, 078,
085, 103, 106 and 153) and also an internal control strain (E4, ribotype
010) previously demonstrated to be intermediately susceptible to
metronidazole.13
Antimicrobial susceptibility testing
Antimicrobial susceptibilities were determined using a previously
described (Wilkins Chalgren) agar incorporation method; this technique
can detect reduced susceptibility of C. difficile to metronidazole.14
In vitro human gut model
We have described previously the use of a triple-stage chemostat human
gut model to study the interplay between antimicrobial agents, the indi-
genous gut microflora and C. difficile.15 The gut model was validated
against physicochemical and microbiological measurements from the
intestinal contents of sudden death victims.16 The gut model is, however,
limited by its inability to simulate immunological and secretory events that
occur in the human colon. The model comprises three pH-maintained (pH
5.5+0.2, vessel 1; pH 6.2+0.2, vessel 2; pH 6.8+0.2, vessel 3) fermen-
tation vessels, top-fed by growth medium at a controlled rate (dilution
rate¼0.015 h21). The gut model is inoculated with a faecal emulsion
(10% w/v in pre-reduced PBS) prepared from C. difficile-negative faeces
of five healthy elderly (.65 years) volunteers. Faecal donors were in good
health and had received no antimicrobial therapy for at least 3 months
prior to commencement of this study.
Experimental design
Time periods for this experiment are displayed in Figure 1. SMT19969 was
evaluated in separate experiments: (i) 31.25 mg/L four times daily dosing
regimen for 7 days; and (ii) 62.5 mg/L four times daily for 7 days. These
dosing regimens were selected to mimic 1× and 2× the clinical regimen
for vancomycin in treating CDI. Following inoculation of the gut model
with faecal emulsion (day 0), themedia pumpwas started and no further
interventions were made for 13 days (period A). Gut microflora were
enumerated every 2 days. C. difficile spores (107 cfu) were prepared
as described previously12 and inoculated into vessel 1 on day 14
(period B). Viable counts of C. difficile and the indigenous gut microflora
and C. difficile cytotoxin titres (Vero cell cytotoxicity assay) were moni-
tored daily. After 7 days a further inoculum of C. difficile spores was
instilled into vessel 1, followed by 33.9 mg/L of clindamycin (four times
daily for 7 days, period C), which was instilled to reflect the concentration
observed in faeces of patients and volunteers.17 Instillation of SMT19969
commenced once high-level cytotoxin titres ≥4 log10-relative units
(RU) were observed on at least two consecutive days (period E).
Following cessation of antimicrobial agent instillation, gut microflora
populations and C. difficile cytotoxin titres were monitored for a further
14 days (period F).
Enumeration of gut microflora and C. difficile
cytotoxin titres
Gut bacterial populations and C. difficile concentrations were determined
as described previously.18 Gut microflora populations cultured were total
facultative anaerobes, total anaerobes (facultative+obligate), lactose-
fermenting Enterobacteriaceae (LFE), enterococci, lactobacilli, bifidobac-
teria, total Clostridium spp., Bacteroides fragilis group (BFG), C. difficile
total viable counts (vegetative C. difficile+spores) and C. difficile spore
viable counts. C. difficile cytotoxin production was monitored using a
Vero cell cytotoxicity assay as described previously.18 Indigenous gut
microflora populations from vessel 1 of the gut models were not deter-
mined; only C. difficile total viable counts, spore counts and cytotoxin titres
were quantified. Possible emergence of C. difficilewith reduced susceptibil-
ity to SMT19969 was monitored by inoculating aliquots from the model
onto Brazier’s CCEY agar incorporating 0.5 mg/L (4×MIC) of SMT19969
throughout the experiment.
Determination of SMT19969 and clindamycin
concentrations
Concentrations of clindamycin achieved in each of the vessels of the gut
model were determined using a microbiological bioassay with the indica-
tor organism Kochuria rhizophila ATCC 9341 as described previously.18
Concentrations of SMT19969 achieved in each of the vessels of the gut
model were determined using a microbiological bioassay with the indica-
tor organism Enterococcus faecalis ATCC 29212. Samples (1 mL) for assay
of antimicrobial concentrations in gut model contents were removed daily
during the gut model experiments and stored at 2208C (bioassay and
HPLC) and assayed retrospectively. Briefly, for bioassays performed with
E. faecalis, the indicator organism was inoculated onto a fresh Columbia
blood agar plate and incubated aerobically for 24 h at 378C. One millilitre
of a standard suspension (0.5 McFarland, 1×107 cfu) in sterile saline was
inoculated into 100 mL molten Mueller–Hinton agar and mixed gently by
inversion. Bioassay dishes were incubated in air at 378C overnight, and
zone inhibition diameters measured with callipers.
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Figure 1. Time scheme in gut model experiments with SMT19969. CLI, clindamycin; CD, C. difficile spores; qds, four times daily.
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Statistical analysis of susceptibility data
MIC data were log2-transformed and assessed for normality and homo-
geneity of variance using Minitab version 16 and SPSS version 20.
Non-parametric testing (Kruskal–Wallis and post hoc tests) for signifi-
cance was performed using these statistical analysis packages. P,0.05
was considered to be statistically significant.
Results
Antimicrobial susceptibility testing
SMT19969 was 7- and 17-fold more active than metronidazole
and vancomycin, respectively (P,0.05), against the panel of 30
genotypically distinct C. difficile PCR ribotypes; metronidazole
was twice as active as vancomycin (P,0.05) (Table 1).
In vitro gut model experiments
Observations during equilibration period
The results observed in vessel 3 of the gut model are shown given
their close similarity to data for vessel 2. Additionally, only the gut
microflora viable counts from the highest dosage (250 mg/L/day
SMT19969) gut model are depicted in this study due to the close
similarity between the two experiments. Viable counts of all bac-
terial groups increased during the steady-state period compared
with those observed on the first day of the experiment (Figures 2
and 3). Gut microfloras in vessels 2 and 3 of the gut models were
dominated by obligate anaerobes, particularly Bifidobacterium
spp. and BFG, with lower observed viable counts of facultatively
anaerobic bacterial groups. Viable counts of indigenous gutmicro-
floras were largely stable by the end of this period.
Observations following instillation of C. difficile spores
Single inocula of C. difficile spores (2×107 cfu) were instilled into
the gut models on day 14 of each experiment. Although some
minor fluctuations in viable counts of the indigenous gut micro-
flora were observed following instillation of C. difficile spores, no
consistent trend was seen across both gut models. C. difficile
viable counts in vessel 1 of both gut models declined at a similar
rate after the initial inoculation of C. difficile spores and there was
no evidence of spore germination, proliferation or cytotoxin pro-
duction (Figures 4 and 5). C. difficile viable counts in vessels 2
and 3 of the gut models increased during the initial stages of
the period, as a consequence of washout from vessel 1, then
declined for the remainder of the period. There was no evidence
of C. difficile germination, proliferation or cytotoxin production
(Figures 4 and 5).
Observations following instillation of clindamycin
Instillation of clindamycin facilitated similar alterations in viable
counts of gut microfloras in both gut models. A sustained reduc-
tion in viable counts of lactobacilli was observed following clin-
damycin instillation (1.5–2.0 log10 cfu/mL), while transient
Table 1. Antibiotic susceptibilities (mg/L) of C. difficile to metronidazole
(MTZ), vancomycin (VAN) and SMT19969
MTZ VAN SMT19969
Geometric mean MIC 0.70 1.53 0.090
MIC50 0.50 2.00 0.125
MIC90 2.00 2.00 0.125
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Figure 2. Mean viable counts (+SE) of obligate anaerobe bacterial groups (log10 cfu/mL) in vessel 3 of the SMT19969 250 mg/L/day gutmodel (period E).
TA, total anaerobes (obligate and facultative).
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minor declines in viable counts of some other groups of obligate
anaerobes was observed (Figures 3 and 4). Marked declines
in viable counts of bifidobacteria were observed during clinda-
mycin instillation (6.0–7.0 log10 cfu/mL) in both gut models.
Additionally, BFG viable counts declined by 1.0 log10 cfu/mL
(Figure 2). Conversely, viable counts of Enterococcus spp.
increased markedly following cessation of clindamycin
instillation (Figure 3). C. difficile remained quiescent during clin-
damycin instillation in both gut models; populations comprised
principally spores, and cytotoxin was undetectable (Figures 4
and 5). Bacterial groups deleteriously affected by clindamycin
instillation largely recovered by the end of the cytotoxin induc-
tion period. LFE viable counts increased markedly during the
cytotoxin induction period.
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Figure 3. Mean viable counts (+SE) of facultative anaerobe bacterial groups (log10 cfu/mL) in vessel 3 of the SMT19969 250 mg/L/day gutmodel (period
E). TFA, total facultative anaerobes.
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Figure 4. C. difficile total viable counts, spore counts (log10 cfu/mL) and cytotoxin titres (RU) in vessel 3 of the gut model dosed with 250 mg/L/day
SMT19969 (period E).
Treatment of simulated CDI in a human gut model
185
JAC
C. difficile germination and proliferation were observed 8 days
(vessel 2, day 35) and 9 days (vessel 3, day 36) after cessation of
clindamycin instillation (Figures 4 and 5). Cytotoxin was demon-
strated in vessel 1 of both gut models 11 days after cessation of
clindamycin instillation. Cytotoxin titres increased to 4 RU in ves-
sels 2 and 3 of both gut models, but remained at 2 RU in vessel 1.
Instillation of SMT19969 commenced 15 days after cessation of
clindamycin instillation (day 42) in both gut models.
Clindamycin concentrations detected in the gut models
Mean clindamycin concentrations (mg/L) observed during the
instillation period in the 125 and 250 mg/L/day gut models were
48.4 and 47.7 (vessel 1), 35.2 and 39.9 (vessel 2), and 36.2 and
38.8 (vessel 3), respectively. Clindamycin was quickly washed
out of the gut model vessels following cessation of instillation,
and was undetectable 6 days after cessation in all vessels of
both experiments.
Effect of SMT19969 on the indigenous gut microflora and
C. difficile
Both SMT19969 dosing regimens demonstrated little antimicrobial
activity against the indigenous gutmicroflora in the two gutmodels
(Table 2). Total Clostridium spp. was the only indigenous gut micro-
flora group for which viable counts declined following SMT19969
instillation (Figure 2). Modest increases in viable counts of LFE were
observed following instillation of both dosing regimens. Vegetative
forms of C. difficile (SMT19969 MIC¼0.125 mg/L) declined during
the SMT19969 instillation period (1.5 log10 cfu/mL over 7 days) in
all vessels of both gut models (Figures 4 and 5). Following cessation
of SMT19969 administration, continued declines in C. difficile
counts by up to a further 2 log10 cfu/mL were observed in the
250 mg/L/day model (Figure 4). C. difficile cytotoxin titres declined
rapidly following commencement of SMT19969 instillation,
with overall declines of 2, 4 and 3 RU observed in vessels 1, 2 and
3, respectively, from days 42 to 48. Following cessation of
SMT19969 instillation, C. difficile vegetative populations remained
detectable and increased slightly by the end of the experiment.
62
0
1
2
Lo
g 1
0 
RU
3
4
5
6
6058565452504846444240383634323028
Time (days)
26242220181614
Lo
g 1
0 
cf
u/
m
L
1.5
2
4
5
6.5
B C D E F
2.5
3
3.5
4.5
5.5
6
Total counts Spore counts Cytotoxin titre
Figure 5. C. difficile total viable counts, spore counts (log10 cfu/mL) and cytotoxin titres (RU) in vessel 3 of the gut model dosed with 125 mg/L/day
SMT19969 (period E).
Table 2. Overall change in viable counts (log10 cfu/mL) of gut microflora
groups and C. difficile, and cytotoxin titres (CYT, RU) during SMT19969
dosing (days 42–48)
Bacterial group
125 mg/L/day 250 mg/L/day
vessel 2 vessel 3 vessel 2 vessel 3
TFA NC NC NC NC
LFE +1.0 +0.6 +0.6 +0.6
BFG NC NC NC NC
Bifidobacteria NC NC NC NC
Lactobacilli NC NC NC NC
Clostridia 22.0 21.7 22.0 21.4
Enterococci NC NC NC NC
Total anaerobes NC NC NC NC
CD TVC 21.5 21.5 21.7 21.4
CD SP 21.3 NC 21.1 20.9
CD CYT 24.0 23.0 24.0 23.0
TFA, total facultative anaerobes; TVC, total viable count; SP, spore count;
CD, C. difficile; NC, no substantial change (+0.5 log10 cfu/mL).
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Cytotoxin was undetectable for the final 6 and 5 days of the 125
and 250 mg/L/day gut models, respectively.
Isolation of C. difficile on breakpoint agars
No C. difficile were isolated from SMT19969 breakpoint agar (4×
MIC) plates during the course of the experiments.
Discussion
The efficacy of existing CDI therapies can be affected by: (i) poor
drug pharmacokinetics, e.g. very low concentrations of metro-
nidazole within the colonic lumen; (ii) fear of bacterial resistance
emergence (e.g. VRE following vancomycin exposure), although a
recent study suggested that these fearsmay be unfounded;19 and
(iii) reduced efficacy against hypervirulent C. difficile ribotypes.6
Emergence of resistance or reduced susceptibility is a concern
for metronidazole,14 especially given its aforementioned poor bio-
availability, although currently no link between reduced suscepti-
bility and treatment failure has been established.20 Emergence of
resistance to fidaxomicin has been documented in a single
instance in the clinical setting; however, rigorous serial passage
studies and human gut model studies have failed to docu-
ment similar findings.11 Similarly, serial passage studies with
SMT19969 demonstrated a low propensity of resistance develop-
ment with mutation frequencies ,3.09×1029.21
The results of the present study show that SMT19969, a novel,
narrow-spectrum, non-absorbable antimicrobial agent, has
high potency against C. difficile in standard agar incorporation
MIC experiments. SMT19969 MICs were 7- and 17-fold lower
than corresponding metronidazole and vancomycin MICs and
are amongst the most potent anti-C. difficile antimicrobial agents
reported. The narrow spectrum of antibacterial activity demon-
strated from SMT19969 susceptibility testing studies22 was
reinforced in the present gut model experiments, in that the
only indigenous microflora group adversely affected following
SMT19969 instillation was Clostridium spp. (2 log10 cfu/mL
decline). This observed anticlostridial activity reflects prior in vitro
susceptibility studies for this genus,23 particularly Clostridium
innocuum, which is often found within the gut models in high
concentrations.
The gut model has proven a valuable tool in the drug develop-
ment setting, both to assess the likelihood of CDI induction by
antibiotics, and to determine the efficacies of novel antimicrobial
agents for treating CDI. Indeed, clinical observations have
reflected in vitro observations in predicting suboptimal efficacy
of the toxin-binding polymer tolevamer,9,24 the superiority of
fidaxomicin compared with vancomycin in treating recurrent
CDI and the low propensity of certain clinical antimicrobial agents
to induce CDI.25–27 Prior gut model studies showed that metro-
nidazole and vancomycin adversely affect the anaerobic gut
microflora (BFG and/or bifidobacteria) and shift the balance
from anaerobe- to facultative-anaerobe-dominated microflora
(LFE and/or lactobacilli and/or enterococci), which is a similar
microflora shift to that observed for antimicrobial agents with a
recognized propensity to induce CDI (clindamycin, ceftriaxone
and cefotaxime). In the present study, neither SMT19969 regimen
adversely affected the normal, anaerobe-dominatedmicroflora in
the gut model vessels, which are analogous to the distal end of
the colon, which may confer this antimicrobial an advantage
over existing therapies. Fidaxomicin was recently demonstrated
to inhibit Bifidobacterium spp. in three of four gut model experi-
ments and facilitated a microflora dominated by LFE, with
reduced BFG concentrations.12 Despite these microflora changes,
fidaxomicin instillation was not associated with recurrent simu-
lated CDI in the gut model; it was suggested that the persistence
of supra-MIC of fidaxomicin prevents C. difficile spore germination
and subsequent simulated recurrence. Metronidazole was
demonstrated as an ineffective treatment for simulated CDI in
the gut model in prior studies, where poor bioactive concentra-
tions of drug within the gut model and signs of recurrent simu-
lated CDI were observed.12
Instillation of SMT19969 into both gut models elicited an
immediate decline in cytotoxin production. Cytotoxin titres
declined substantially by the end of period E, and were at the
limit of detection 2 days later in both high and low SMT19969 dos-
age models. The decline in C. difficile total viable counts observed
following SMT19969 instillationwas incremental over several days
and indicated a bacteriostatic mechanism of action for this anti-
biotic under these experimental conditions. However, in standard
in vitro testing SMT19969 demonstrates bactericidal activity with
.5 log reduction in cfu/mL at 24 h.28 These declines in C. difficile
concentrations following SMT19969 instillation in the gut model
are similar to, or better than, declines observed following instilla-
tion of vancomycin into the gut model,29,30 although in the pre-
sent study total viable counts remained above spore counts in
the SMT19969 dosing period. In a recent in vivo study using the
hamster model of CDI, SMT19969 elicited complete clearance of
viable C. difficile following commencement of dosing (R. Vickers,
unpublished results), and in the Phase I clinical trial of
SMT19969, clostridial viable counts were below the lower limits
of detection for viable counting (whereas other gut microflora
groups were unaffected).31 The differences between the present
in vitro study and recent in vivo studies with SMT19969 probably
reflect a suboptimal formulation used in the present experiments
that has been shown to result in significantly reduced efficacy in
the hamster model of CDI (R. Vickers, unpublished results). Visible
precipitates of SMT19969 were observed following instillation of
the drug and persisted for the duration of the experiment in
both gut models. Poor solubility also hampered efforts to deter-
mine the dissolved (bioavailable) fraction of SMT19969, and
therefore some caution must be exercised when interpreting the
antimicrobial activity of SMT19969 in these gut model studies.
Cytotoxin titres increased slightly during period F (rest period),
but to a relatively low titre (2 RU), and titres were below the limits
of detection for the last 5–6 days of both experiments. The spor-
adic spikes in total viable count and low-level cytotoxin observed
during period F may be due to the release of vegetative C. difficile
from biofilms within the gut models; both the organism and its
cytotoxins have been demonstrated to be present in the complex,
multispecies biofilms within the gut model vessels (G. S. Crowther,
M. H. Wilcox and J. Freeman, unpublished results).32 Instillation of
SMT19969 curtailed the production of cytotoxin by C. difficile ribo-
type 027, noting that prior gut model studies have consistently
demonstrated a substantially longer (.23 days), but not higher,
peak cytotoxin titre by this virulent ribotype.18
The results of the present study, combined with a good Phase I
safety and tolerability profile, and superior efficacy to vancomycin
in treating CDI in the hamster model,21 indicate that further stud-
ies with SMT19969 are warranted to determine its efficacy as a
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potential CDI therapeutic option. Improvements to the solubility
of SMT19969, or reduced dosing to aid dissolution, may facilitate
the demonstration of enhanced efficacy in vitro and in vivo in
future studies. In particular, an assessment of the efficacy of
SMT19969 in preventing recurrent CDI both in vitro and in vivo
would help to determine whether this is an area in which this
novel antimicrobial agent may outperform other CDI therapies.
Indeed, the extremely narrow spectrum of antibacterial activity
of SMT19969 is attractive, and theoretically suggests a reduced
likelihood of CDI recurrence due to reduced perturbation of colonic
colonization resistance.
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